© Queen’s Printer and Controller of HMSO 2013Severe allergic rhinitis uncontrolled by conventional medication can substantially affect quality of life. Immunotherapy involves administering increasing doses of a specific allergen, with the aim of reducing sensitivity and symptomatic reactions. Recent meta-analyses have concluded that both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are more effective than placebo in reducing symptoms. It is uncertain which route of administration is more effective and whether or not treatment is cost-effective.National Institute for Health Research Health Technology Assessment programm

Barton, P

Dretzke, J

Fry-Smith, A

Huissoon, A

Kaambwa, B

Meadows, A

Meads, C

Novielli, N

Health Technology Assessment

English

PubMed

BACKGROUND: Severe allergic rhinitis uncontrolled by conventional medication can substantially affect quality of life. Immunotherapy involves administering increasing doses of a specific allergen, with the aim of reducing sensitivity and symptomatic reactions. Recent meta-analyses have concluded that both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are more effective than placebo in reducing symptoms. It is uncertain which route of administration is more effective and whether or not treatment is cost-effective.OBJECTIVE: To determine the comparative clinical effectiveness and cost-effectiveness of SCIT and SLIT for seasonal allergic rhinitis in adults and children.DATA SOURCES: Electronic databases {MEDLINE, EMBASE, The Cochrane Library [Cochrane Central Register of Controlled Trials (CENTRAL)], NHS Economic Evaluation Database (NHS EED)} and trial registries (from inception up to April 2011).REVIEW METHODS: Standard systematic review methods were used for study selection, data extraction and quality assessment. Double-blind randomised, placebo-controlled trials of SCIT or SLIT, or of SCIT compared with SLIT, and economic evaluations were included. Meta-analysis and indirect comparison meta-analysis and meta-regression were carried out. A new economic model was constructed to estimate cost-utility.RESULTS: Meta-analyses found statistically significant effects for SCIT and SLIT compared with placebo across a number of outcome measures and for the vast majority of subgroup analyses (type and amount of allergen, duration of treatment). There was less evidence for children, but some results in favour of SLIT were statistically significant. Indirect comparisons did not provide conclusive results in favour of either SCIT or SLIT. Economic modelling suggested that, when compared with symptomatic treatment (ST), both SCIT and SLIT may become cost-effective at a threshold of £20,000-30,000 per quality-adjusted life-year (QALY) from around 6 years, or 5 years for SCIT compared with SLIT (NHS and patient perspective).LIMITATIONS: It is uncertain to what extent changes in the outcome measures used in the trials translate into clinically meaningful benefits. Cost-effectiveness estimates are based on a simple model, limited data and a number of assumptions, and should be seen as indicative only.CONCLUSIONS: A benefit from both SCIT and SLIT compared with placebo has been consistently demonstrated, but the extent of this effectiveness in terms of clinical benefit is unclear. Both SCIT and SLIT may be cost-effective compared with ST from around 6 years (threshold of £20,000-30,000 per QALY). Further research is needed to establish the comparative effectiveness of SCIT compared with SLIT and to provide more robust cost-effectiveness estimates.FUNDING: The National Institute for Health Research Health Technology Assessment programme.</p

University of Birmingham Research Portal

A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis

Brunel University Research Archive

(JD) has been a systematic reviewer with WMHTAC since

(p < 0.00001); I 2= 87% Test for overall effect: z = 3.14 (p =

(p = 0.0005); I 2 = 65% Test for overall effect: z = 2.70 (p =

(p = 0.0009); I 2 = 49% Test for overall effect: z =

(p = 0.02); I 2 = 51% Test for overall effect: z = 2.76 (p =

(p = 0.26); I 2 = 22% Test for overall effect: z = 2.14 (p =

(p = 0.48); I 2 = 0% Test for overall effect: z = 4.80 (p <

(p = 0.92); I 2 = 0% Test for overall effect: z = 3.51 (p =

[Erratum published in Allergy 2009;64:1394–401.] http://dx.doi. org/10.1111/j.1398-9995.2008.01875.x 109. Palma-Carlos

[Lowered effectiveness of immunotherapy for cypress pollinosis by using Japanese cedar pollen extract.] Jp J Allergol 2008;57:558–61 Japanese paper identified as likely to be included after preliminary translation. Full translation not obtained

[Treatment of allergy to mushrooms.] Anales del Sistema Sanitario de Navarra 2003;26(Suppl. 2):129–37 Not all participants

1. Is there a clear statement of the decision problem?

16. Are the data identification methods transparent and appropriate given the objectives of the model?

64. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases.

A double-blind study.

A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. Clinical results. Allergy 1986;41:131–40. http://dx.doi.org/10.1111/j.1398-9995.1986. tb00289.x 74. Fontana VJ,

A r i a n o

A single dose desensitization for summer hay fever. Results of a double blind study1988. Eur J Clin Pharmacol 1990;38:77–9. http://dx.doi.org/10.1007/BF00314808 48. Di Stanislao

A two-year aerobiological study and immunotherapy follow-up with Phoenix sylvestris pollen to seasonal allergic patients from West Bengal, India. J World Allergy Org

Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev

Allergen-specific immunotherapy with recombinant grass pollen allergens.

allergic inflammation. Clin Exp Allergy 1991;21:206–10 Duplicate of study included in Cochrane review (Varney

Allergic rhinitis and its impact on asthma (ARIA)

Allergic rhinitis and its impact on asthma.

Allergy Appl Immunol 1971;40:448–53 Appears to be relevant RCT in 21 patients

An assessment of sustained efficacy and safety of a 300 IR five-grass pollen sublingual immunotherapy tablet in adults with grass pollen induced allergic rhinoconjunctivitis during a 3-year treatment study.

Ann Allergy Asthma Immunol 2008;101:316–24. http://dx.doi.org/10.1016/S1081-1206

Appendix 10 Reasons for exclusion: costeffectiveness studies and reviews Reference Reason for exclusion

Appendix 7 Results of subgroup analyses Subcutaneous immunotherapy Comparison 1 Subcutaneous immunotherapy compared with placebo, all studies Outcome or subgroup No. of studies No. of participants

Bayesian modeling using WinBUGS.

BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy

Burden of allergic disease in the UK secondary analyses of national databases. Clin Exp Allergy

Burden of allergic disease in the UK secondary analyses of national databases. Clin Exp Allergy 2004;34:520–6. http://dx.doi. org/10.1111/j.1365-2222.2004.1935.x 11. White

Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjuctivitis. Annals Allergy Asthma Immunol 2004;93:425–30. http://dx.doi.org/10.1016/S1081-1206(10)61408-1 98. Casanovas

Child Educ Pract 2011;96:91–100. http://dx.doi.org/10.1136/adc.2010.183095 9. Burgess

Clin Immunol 2004;114:851–7. http://dx.doi.org/10.1016/j.jaci.2004.07.012 58. Polosa

Clin Immunol 2006;117:134–40. http://dx.doi.org/10.1016/j.jaci.2005.09.036 160. Ceuppens

Clin Immunol 2006;117:810–16. http://dx.doi.org/10.1016/j.jaci.2005.11.039 144. Creticos PS,

Clin Immunol 2006;117(American Academy of Allergy, Asthma and Immunology 62nd Annual Meeting,

Clin Immunol 2006;118:434–40. http://dx.doi.org/10.1016/j.jaci.2006.05.003 94. Amar

Clin Immunol 2008;121:227–32 Not EE, does not report relevant information

Clin Immunol 2009;124:150–6. http://dx.doi.org/10.1016/j.jaci.2009.04.037 95. Andre

Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy.

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study.

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebocontrolled, double-blind, double-dummy study.

ClinicalTrials.gov website. 2nd Pivotal Study rPhleum: adults and adolescents with rhinoconjunctivitis +/– controlled asthma.

ClinicalTrials.gov website. Evaluation of safety and efficacy of specific immunotherapy with recombinant major allergens of timothy grass pollen adsorbed onto aluminium-hydroxide

ClinicalTrials.gov website. Long-term effects of sublingual grass therapy.

ClinicalTrials.gov website. Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis.

ClinicalTrials.gov website. Safety and efficacy of recombinant grass pollen allergen cocktail in the treatment of allergic rhinoconjunctivitis.

Cochrane Handbook for Systematic Reviews of Interventions.

Cochrane systematic review: safety profile of sublingual immunotherapy (SLIT) for allergic rhinitis (AR).

Comparison 15 Sublingual immunotherapy compared with placebo, children Outcome or subgroup No. of studies No.

Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol

Congress of the European Academy of Allergology and Clinical Immunology (EAACI),

Consumables and general supplies. URL: www.medisave.co.uk/consumablesgeneral-supplies.html (accessed 17

Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis: a Northern European perspective.

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced thinoconjunctivitis: A Northern European perspective. Clin Exp Allergy

Cost-effectiveness of grazax in the paediatric population for the treatment of grass pollen induced rhinoconjunctivitis in Germany. Value Health

Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-exisiting with asthma. Allergy

Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 2008; 63:1624–9 Cost-effectiveness study

Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol

Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria.

Data mainly from PAT study272 Results z Three-year average direct costs for the five forms of immunotherapy were:

Die jährlichen Kosten der allergischen Rhinitis und des Asthmas in der Bundesrepublik Deutschland.

Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D. pt.) in children. Pediatr Allergy Immunol 1997;8:21–7. http:// dx.doi.org/10.1111/j.1399-3038.1997.tb00138.x 207.

e d i c a t i o n s c o r e s M o d e l ( c o v a r i a t e i n c l u d e d i n t h e m o d e l ) n P a r a m e t e r S C I T v s p l a c e b o : a d i r e c t c o m p a r i s o n s (

Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol

Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Brief record. Ann Allergy Asthma Immunol 2008;100:482–9. http://dx.doi. org/10.1016/S1081-1206(10)60475-9 226. Berto

Effectiveness of high dose sublingual immunotherapy to induce a stepdown of seasonal asthma: a pilot study.

Effectiveness of hyposensitization therapy in ragweed hay-fever in children. J Am Med Assoc 1966;195:985–92 Excluded from Cochrane review as no standardised allergen extract Sublingual immunotherapy Reference Details Okubo

Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol 2011;127:502–8. http://dx.doi.org/10.1016/j. jaci.2010.11.036 153. Ljorring

Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double blind, placebo-controlled trial. Ann Allergy Asthma Immunol

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis.

Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double blind, placebo-controlled study. Pediatr Pulmonol 2001;32:49–55. http://dx.doi.org/10.1002/ppul.1088 205. Cao

Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol

Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004;59:498–504. http://dx.doi. org/10.1111/j.1398-9995.2004.00457.x 85. Bufe

Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2010;40:1062–70. http:// dx.doi.org/10.1111/j.1365-2222.2010.03521.x 149.

European outcomes amongst allergic rhinoconjunctivitis patients participating in a placebo-controlled study of ultra short course subcutaneous immunotherapy (uSCIT) conducted during the 2007 grass pollen season. Allergy

Evaluation Database) Refer to The Cochrane Library effectiveness search strategy above.

Favours SCIT Favours placebo Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI SCIT Placebo Standard mean difference Standard mean difference IV,

Favours SLIT Favours placebo Study or subgroup Mean SD Total Mean SD Total Weight IV, random, 95% CI SLIT Placebo Standard mean difference Standard mean difference IV,

Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.

Funnel plot: SCIT vs placebo, SSs. SE, standard error. FIGURE 100 Funnel plot: SLIT vs placebo, SSs. SE, standard error.

Further analysis of Jutel 2005, included in Cochrane review Keiding

General practice consultation rates for allergic rhinitis in England show an increase in new patients with this diagnosis year on year between

Handbook for Systematic Reviews of Interventions.

Health economic modeling of allergen-specific immunotherapy in seasonal allergic rhinitis from a health care payer’s perspective.

How to formulate research recommendations.

Immunological Biomarkers of Grass Allergen Tablets in Grass Pollen Rhinoconjunctivitis Patients. J Allergy Clin Immunol 2008;121(American Academy of Allergy, Asthma and Immunology, 64th Annual Meeting,

Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol

immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007;178:4658–66 No relevant outcomes reported

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445–55. http://dx.doi.org/10.1056/NEJMoa052916 145. DuBuske

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51:430–3. http://dx.doi. org/10.1111/j.1398-9995.1996.tb00155.x 34. DesRoches

Immunotherapy with Alternaria alternata: present and future. Allergol Immunopathol 2007;35:259–63 Review Martínez Cócera

Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment. Clin Exp Allergy 2009;39:394–400. http://dx.doi.org/10.1111/j.1365-2222.2008.03153.x 203.

intermittent* or TX season* or TX spring or TX summer or TX pollen* or TX grass* or TX birch or TX ragweed or TX tree* or TX weed* or TX mugwort or TX willow S9 TX alder or TX poaceae

Intraseasonal short-time updosing with SQ-standardised subcutaneous immunotherapy in patients with intermittent allergic rhinitis: a new therapeutic option.

A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis

Abstract

Similar works

Full text

Available Versions

University of Birmingham Research Portal

Brunel University Research Archive

Directory of Open Access Journals

University of Birmingham Research Portal

Crossref